SCY-247

May 11, 2026: SCYNEXIS, Inc. (NASDAQ: SCYX) reported Q1 2026 results and provided program updates, highlighting completion of its acquisition of Poxel S.A.’s PXL-770 (renamed SCY-770), a selective direct AMPK activator for autosomal dominant polycystic kidney disease (ADPKD). The company expects to initiate a Phase 2 proof-of-concept ADPKD study in Q4 2026, with an early efficacy readout anticipated in 2H 2027; SCY-770 has FDA Orphan Drug Designation.

SCY-247 (second-generation “fungerp” antifungal): SCYNEXIS dosed the first patient in a Phase 1 study of the IV formulation on Feb. 26, 2026, with topline data expected in Q3 2026. Following completion of an oral Phase 1 study showing tolerability and preliminary target exposures, SCYNEXIS is accepting requests for oral SCY-247 via an expanded access program. The company presented nine papers on SCY-247 at ESCMID (April 2026) and presented additional data at IMARI (Jan. 28–30, 2026). FDA granted SCY-247 QIDP, Fast Track, and Orphan Drug Designations.

Financing/partner update: A private placement closed April 1, 2026 with net proceeds of ~$37.2M (and potential additional warrant proceeds). GSK plans to relaunch BREXAFEMME (ibrexafungerp), with SCYNEXIS eligible for up to ~$146M in annual net sales milestones. Cash runway is projected to mid-2029.